An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2013
At a glance
- Drugs Romidepsin (Primary)
- Indications Cancer; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jun 2012 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.